Peptide therapy is usually not covered by insurance, and the reason is less about the peptides than about how they reach you. Most are dispensed as compounded preparations, and compounded drugs are not FDA-approved[1]. Health coverage, public and private, is built around approved drugs listed on a formulary, so a compounded prescription starts outside that system.
That is why the prices on this site’s price boards are cash prices, and why the fees around them matter as much as the drug. The table below sorts the compounds this site tracks by whether an approved product exists at all.
| Status | Compounds | What a plan can cover |
|---|---|---|
| Has an FDA-approved product | Semaglutide, Tirzepatide, Liraglutide, Orforglipron, PT-141 (bremelanotide), Tesamorelin | The approved brand, subject to the plan's formulary and the statutory exclusions below |
| Compounded only | Sermorelin, NAD+, Glutathione, GHK-Cu | No approved product exists to list; coverage of a compounded preparation is the plan's call |
Medicare Part D and Medicaid
For Medicaid, a covered outpatient drug is, with narrow exceptions, a prescription drug approved as safe and effective under the Federal Food, Drug, and Cosmetic Act[2]. Medicare Part D builds its definition of a covered drug on that same Medicaid definition[3].
Both programs then carve out classes by use. Medicaid may exclude agents used for weight loss, for cosmetic purposes or hair growth, and for sexual or erectile dysfunction[2]. Part D excludes the classes Medicaid may exclude, with a few named exceptions, and separately excludes drugs used for sexual or erectile dysfunction unless the drug treats another approved condition[3].
Those carve-outs line up closely with how peptides are marketed. A skin-lightening glutathione protocol reads as cosmetic, and PT-141 is a sexual-function drug, which is why the PT-141 cost guide assumes cash.
Sermorelin: no approved product to cover
Sermorelin once had an approved brand, GEREF, for growth hormone deficiency in children[4]. Its maker discontinued it, and FDA withdrew approval of both GEREF applications effective June 18, 2009[4]. FDA later determined the product was not withdrawn for reasons of safety or effectiveness[4].
That determination matters for compounding, but it does not put a product back on any formulary. With no approved sermorelin on the market, there is no brand for a plan to list, and a compounded prescription is paid out of pocket unless a plan chooses otherwise.
Private plans
Employer and marketplace plans set their own formularies, and nothing here can say what a given plan pays for. What can be said is where to look. A formulary lists drugs by name, so ask the plan whether it has any process for compounded prescriptions, and whether prior authorization or an exception request applies.
If insurance will not pay
A tax-advantaged account may still help, because the rules there turn on whether a drug is prescribed for medical care rather than on formularies. The HSA and FSA guide covers those rules. Before paying cash, compare quotes at the same form and dose with every fee added back, as set out in the peptide therapy cost guide. Then ask the seller whether it offers a superbill you could submit to your plan yourself.